Role of microbiota-derived short-chain fatty acids in cancer development and prevention

Biomed Pharmacother. 2021 Jul:139:111619. doi: 10.1016/j.biopha.2021.111619. Epub 2021 Apr 24.

Abstract

Following cancer, cells in a particular tissue can no longer respond to the factors involved in controlling cell survival, differentiation, proliferation, and death. In recent years, it has been indicated that alterations in the gut microbiota components, intestinal epithelium, and host immune system are associated with cancer incidence. Also, it has been demonstrated that the short-chain fatty acids (SCFAs) generated by gut microbiota are vitally crucial in cell homeostasis as they contribute to the modulation of histone deacetylases (HDACs), resulting effected cell attachment, immune cell immigration, cytokine production, chemotaxis, and the programmed cell death. Therefore, the manipulation of SCFA levels in the intestinal tract by alterations in the microbiota structure can be potentially taken into consideration for cancer treatment/prevention. In the current study, we will explain the most recent findings on the detrimental or protective roles of SFCA (particularly butyrate, propionate, and acetate) in several cancers, including bladder, colon, breast, stomach, liver, lung, pancreas, and prostate cancers.

Keywords: Cancer; HDAC; Immune system; Microbiota; SCFAs.

Publication types

  • Review

MeSH terms

  • Animals
  • Anticarcinogenic Agents / pharmacology*
  • Carcinogenesis / drug effects*
  • Fatty Acids, Volatile / pharmacology*
  • Gastrointestinal Microbiome
  • Humans
  • Microbiota*

Substances

  • Anticarcinogenic Agents
  • Fatty Acids, Volatile